Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.20 +1.6%	$5.05	$3.96 ▼ $9.85	$2.26B	0.28	2.62 million shs	1.46 million shs
IBRX ImmunityBio	$2.79 +1.1%	$2.67	$1.83 ▼ $7.48	$2.44B	0.14	6.06 million shs	4.49 million shs
IOVA Iovance Biotherapeutics	$1.88 +1.6%	$2.38	$1.64 ▼ $12.51	$617.78M	0.86	8.96 million shs	9.70 million shs
XENE Xenon Pharmaceuticals	$32.17 +2.2%	$33.01	$26.74 ▼ $46.00	$2.42B	1.09	564,688 shs	784,424 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	-0.97%	+3.47%	+37.15%	-13.09%	-10.15%
IBRX ImmunityBio	-3.83%	-11.82%	+9.09%	+0.73%	-61.98%
IOVA Iovance Biotherapeutics	-6.57%	-11.06%	+3.93%	-46.84%	-76.90%
XENE Xenon Pharmaceuticals	-1.75%	-1.66%	+5.85%	-9.77%	-16.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	4.1575 of 5 stars	1.9	2.0	4.0	3.8	3.3	1.9
IBRX ImmunityBio	2.3437 of 5 stars	3.6	2.0	0.0	1.9	1.7	0.6
IOVA Iovance Biotherapeutics	4.6306 of 5 stars	4.3	1.0	4.2	1.8	4.2	1.3
XENE Xenon Pharmaceuticals	3.0392 of 5 stars	4.5	4.0	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	1.86	Reduce	$7.42	19.72% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	339.07% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	550.12% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	70.40% Upside

Current Analyst Ratings Breakdown

Latest IOVA, IBRX, XENE, and BHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.24	$7.84 per share	0.79	($0.89) per share	-6.96
IBRX ImmunityBio	$31.22M	78.87	N/A	N/A	($0.57) per share	-4.89
IOVA Iovance Biotherapeutics	$164.07M	3.83	N/A	N/A	$2.33 per share	0.81
XENE Xenon Pharmaceuticals	$9.43M	261.76	N/A	N/A	$9.90 per share	3.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.33	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.23	N/A	N/A	N/A	N/A	-32.44%	-30.84%	8/6/2025 (Estimated)

Latest IOVA, IBRX, XENE, and BHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	N/A	1.35	0.97
IBRX ImmunityBio	N/A	2.22	2.05
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
XENE Xenon Pharmaceuticals	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
IBRX ImmunityBio	8.58%
IOVA Iovance Biotherapeutics	77.03%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.12%
IBRX ImmunityBio	76.79%
IOVA Iovance Biotherapeutics	10.30%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.03 million	Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.50 million	Optionable

IOVA, IBRX, XENE, and BHC Headlines

Recent News About These Companies

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

June 24 at 8:30 AM | globenewswire.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 3.4% - Here's Why

June 16, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages

June 15, 2025 | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from Analysts

June 15, 2025 | marketbeat.com

Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

June 12, 2025 | marketbeat.com

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

June 11, 2025 | zacks.com

Cantor Fitzgerald Estimates XENE FY2026 Earnings

June 10, 2025 | marketbeat.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

June 2, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE

May 31, 2025 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

May 30, 2025 | marketbeat.com

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 26, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP

May 25, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday

May 15, 2025 | insidermonkey.com

Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events

May 15, 2025 | proactiveinvestors.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, IBRX, XENE, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

$6.20 +0.10 (+1.56%)

Closing price 03:59 PM Eastern

Extended Trading

$6.21 +0.01 (+0.24%)

As of 07:56 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

ImmunityBio NASDAQ:IBRX

$2.79 +0.03 (+1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 +0.01 (+0.50%)

As of 07:58 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Iovance Biotherapeutics NASDAQ:IOVA

$1.88 +0.03 (+1.62%)

Closing price 04:00 PM Eastern

Extended Trading

$1.89 +0.01 (+0.53%)

As of 07:50 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Xenon Pharmaceuticals NASDAQ:XENE

$32.17 +0.68 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$32.16 -0.01 (-0.03%)

As of 05:59 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time